



NEWS RELEASE

ANTARES PHARMA TO PRESENT AT THE 25TH ANNUAL OPPENHEIMER HEALTHCARE CONFERENCE

EWING, NJ, December 3, 2014 -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P. Hobbs, President and Chief Executive Officer, will present at the 25th Annual Oppenheimer Healthcare Conference on Wednesday, December 10, 2014 at 3:55 p.m. Eastern Time.

A live webcast of the presentation will be available via the "Investor Information/Webcasts" page of the Antares website, www.antarespharma.com. A replay of the webcast will also be archived on Antares' website for 90 days following the presentation.

About Antares Pharma

Antares Pharma focuses on self-administered parenteral pharmaceutical products. The Company markets OTREXUP[™] (methotrexate) injection for subcutaneous use in the treatment of adults with severe active rheumatoid arthritis and children with active polyarticular juvenile idiopathic arthritis. LEO Pharma markets OTREXUP[™] to dermatologists for adults with severe recalcitrant psoriasis. Antares Pharma is also developing QuickShot[®] Testosterone for testosterone replacement therapy. The Company's technology platforms include VIBEX[®] disposable Medi-Jet, disposable multi-use pen injectors and reusable needle-free injectors marketed as Tjet[®] and Zomajet[®] by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin[®] [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX[®] epinephrine and several other products. In the U.S. Antares has received FDA approval for Gelnique 3%[™] (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin[®] (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda.

Contact:

Jack Howarth
Vice President, Corporate Affairs
609-359-3016
jhowarth@antarespharma.com